The American Society of Clinical Oncology (the Society) is governed by a volunteer Board of Directors (including five Board officers) elected by ASCO’s member oncologists. The ASCO Chief Executive Officer serves on the Board as well. Elected Board members are cancer physicians and clinical researchers who volunteer their time to ASCO. Board members are not paid for their service, although their institutions receive stipends to partially cover the time and administrative resources dedicated to ASCO.

View the Disclosures for the Society Board of Directors at the bottom of each individual’s bio. Please direct any questions related to Board members' disclosures to our COI team.

Clifford A. Hudis, MD, FACP, FASCO
Chief Executive Officer, ASCO; Executive Vice Chair, and Conquer Cancer, the ASCO Foundation
x

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through research, education, and promotion of the highest quality, equitable patient care by the Society’s nearly 50,000 members.

Read Dr. Hudis’ Q&A on ASCO Connection.

View current ASCO disclosure here.

Lynn Mara Schuchter, MD, FASCO
ASCO President
x

Dr. Schuchter is chief of the Division of Hematology-Oncology at the Abramson Cancer Center at the University of Pennsylvania, director of the Tara Miller Melanoma Center at the Abramson Cancer Center, and the Madlyn and Leonard Abramson Professor of Clinical Oncology at the Perelman School of Medicine of the University of Pennsylvania. Dr. Schuchter is a clinical investigator in the area of melanoma and has a strong commitment to mentorship.  Dr. Schuchter served on the ASCO Board of Directors from 2009 to 2012. She has served on numerous ASCO committees, including terms as chair of Annual Meeting Scientific Program Committee, Cancer Research Committee, and Cancer Communications Committee, and as an editor on the Journal of Clinical Oncology Editorial Board. In 2019, she was recognized with the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award from Conquer Cancer, the ASCO Foundation.

View current ASCO disclosure here.

Robin Zon, MD, FASCO, FACP
ASCO President-Elect
x

Dr. Zon currently serves as the Director of Breast Cancer Oncology at the Cincinnati Cancer Advisors (CCA), a provider of no-cost second opinions to recently diagnosed cancer patients in or near the Greater Cincinnati area. Prior to joining CCA, Dr. Zon served as Past President, and is now Physician Emeritus at Michiana Hematology Oncology in Mishawaka, IN. She formerly served as Medical Director of Oncology Research at Memorial Hospital and NCI CCOP Associate and then Principal Investigator until 2013 for the Northern Indiana Cancer Research Consortium, the only NCI designated Community Cancer Oncology Program in the state of Indiana. Dr. Zon is an active volunteer for ASCO, most recently being awarded ASCO’s Advocate of the Year for her significant advocacy work on behalf of individuals living with cancer and their cancer care teams and was the recipient of ASCO’s Distinguished Achievement Award. Dr. Zon is a Past Chair of ASCO’s Government Relations Committee, where she provided distinguished leadership in the society’s advocacy efforts. She also served on the Board of Directors from 2010 to 2013, along with participating in many other ASCO related responsibilities.

View current ASCO disclosure here

Eric P. Winer, MD, FASCO
Chair of the Board
x

Dr. Winer was elected to serve as the ASCO President in 2022-2023. He is the Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale New Haven. Before then, he served as the chief clinical development officer, senior vice president for medical affairs, Director of the Dana-Farber/Harvard SPORE in Breast Cancer, and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He has also served as a professor of medicine at Harvard Medical School. Dr. Winer served on the ASCO Board of Directors from 2011 to 2015, and has served as chair of the ASCO Government Relations Committee, Cancer Communications Committee, and Health Services Research Committee, among numerous volunteer roles. He was the recipient of the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School in 2020. He has also received numerous awards for his breast cancer research, most notably ASCO’s Gianni Bonadonna Breast Cancer Award and Lecture in 2017 and the William L. McGuire Memorial Lecture Award in 2016 at the San Antonio Breast Cancer Symposium.

View current ASCO disclosure here

Everett E. Vokes, MD, FASCO
Past President
x

Dr. Vokes specializes in head and neck and lung cancers. He is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medicine and Biological Sciences. He is the former leader of the Respiratory Committee of the Alliance ( formerly  Cancer and Leukemia Group B ) and serves on the editorial boards of several journals. He is a past chair of the Annual Meeting Education Committee, Annual Meeting Scientific Program Committee, and a member of the Conquer Cancer Development and Fundraising Committee, and the Cancer.Net Editorial Board. He served as an elected member of the ASCO Nominating Committee, and on the Board of Directors from 2009-2012.

View current ASCO disclosure here

Elizabeth R. Plimack, MD, MS, FASCO
Board Seat: Undesignated Specialty; Treasurer
x

Dr. Plimack serves as at the Deputy Director of Fox Chase Cancer Center in Philadelphia. She is a professor of medical oncology and the director of genitourinary clinical research at the center. She is a past member and track chair of the ASCO Scientific Program Committee, Genitourinary (Non-Prostate) Cancer track. She serves as a member on the Board’s Finance Committee and is the Board Liaison to the Cancer Communications Committee. Dr. Plimack received a Conquer Cancer Merit Award at the 2008 Genitourinary Cancers Symposium.

Read Dr. Plimack's Q&A on ASCO Connection.

View current ASCO disclosure here.

Taofeek K. Owonikoko, MD, PhD, FASCO
Board Seat: Medical Oncologist; Treasurer-Elect
x

Dr. Owonikoko is the Executive Director of the University of Maryland’s NCI-designated Marlene and Stewart Greenebaum Comprehensive Cancer Center. He is also the Senior Associate Dean of Cancer Programs at the University of Maryland’s School of Medicine and the Associate Vice President of Cancer Programs at the University of Maryland, Baltimore. A translational physician-scientist, board-certified in Medical Oncology, Hematology, and Internal Medicine, he has a clinical focus on the management of patients with lung cancer. His research interests span the spectrum of preclinical experimental therapeutics, biomarker discovery, and translation of promising laboratory findings into lung cancer clinical trials.

He is currently an elected member of the Board of the American Society of Clinical Oncology (ASCO) and the Treasurer-Elect of ASCO. He serves as an Editorial Board Member for several highly regarded academic journals including Cancer, Journal of Thoracic Disease, and Translational Lung Cancer Research. Dr. Owonikoko is a member of the American College of Physicians, American Society for Hematology, the Society for Immunotherapy of Cancer, and the International Association for the Study of Lung Cancer. Lastly, he has been an NIH Study Section Member for the past eleven years and is a chartered member for the NIH Clinical Oncology Study section.

Dr. Owonikoko has authored/co-authored more than 250 peer-reviewed original manuscripts including reports of original research in leading journals such as the New England Journal of Medicine, Lancet, Cell, Science, Nature, JCO, Lancet Oncology, Cancer Discovery, and Cancer Cell. His work has been broadly cited with more than 48,000 citations and an h-index of 86. He has received peer-reviewed extramural grant funding in support of his research from the US National Institutes of Health, Department of Defense, private foundations, and pharmaceutical partners.

View current ASCO disclosure here.

Fredrick Chite Asirwa, MD, MBChB
Board Seat: Designated International Oncologist
x

Dr. Asirwa is the chief oncologist and hematologist and the CEO/executive director of the International Cancer Institute in Kenya. He is a member of the ESMO/ASCO Task Force for Global Curriculum for Training in Medical Oncology, among other past volunteer appointments. He is currently leading various cancer care access, innovation and personalized medicine programs in sub-Saharan Africa.

View current ASCO disclosure here.

 

Lisa A. Carey, MD, FASCO
Board Seat: Undesignated Specialty
x

Dr. Carey is Deputy Director for Clinical Sciences at Lineberger Comprehensive Cancer Center and the L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research at the University of North Carolina Lineberger Comprehensive Cancer Center. She is also co-chair of the Alliance cooperative group Breast Committee and a member of the NCI Breast Cancer Steering Committee. Dr. Carey is a member of ASCO’s Breast Cancer Guideline Advisory Group. She previously served the Society as chair of the Nominating Committee, chair of the Professional Development Committee, track leader of the Annual Meeting Education Committee, and a member of the Society’s Audit Committee and the Journal of Clinical Oncology editorial board.

View current ASCO disclosure here

Tara O. Henderson, MD, FASCO, MPH
Board Seat: Pediatric Oncologist
x

Dr. Henderson is a professor of pediatrics, Division Chief of Pediatric Hematology, Oncology and Stem Cell Transplantation and director of the Childhood Cancer Survivor Center at the University of Chicago, and co-leader of the cancer prevention and control program for the University of Chicago Comprehensive Cancer Center. She is a graduate of the 2018 President Leadership Scholars program and a 2015 graduate of the ASCO Leadership Development Program. Dr. Henderson is the chair of the ASCO Adolescent and Young Adult (AYA) Survivorship Work Group and a past member of several ASCO committees, including the Government Relations Committee, the Survivorship Guideline Advisory Group, the Conquer Cancer Grants Selection Committee and Osteoporosis in Survivors of Adult Cancers Expert Panel. She is the past chair of the Cancer Survivorship Committee, a member of the Society Board’s Audit Committee and a liaison to the Conquer Cancer Grants Selection Committee.

View current ASCO disclosure here.

 

Carolyn B. Hendricks, MD, FASCO
Board Seat: Designated Community Oncologist
x

Dr. Hendricks is a practicing medical oncologist specializing in breast cancer genetics, screening, and treatment at Maryland Oncology Hematology PA. She is immediate past chair of the Government Relations Committee, past chair of the ABIM-ASCO Breast Cancer Exam Subcommittee, and a member of the Practice Quality Improvement Steering Group, among other volunteer service. Dr. Hendricks was honored as Advocate of the Year by the Association for Clinical Oncology in 2019.

View current ASCO disclosure here.

 

Mariana Chavez Mac Gregor, MD, MSc
Board Seat: Undesignated Specialty
x

Dr. Chavez Mac Gregor is an Associate Professor in the Department of Health Services Research and an Associate Professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center. She is Co-Chair of the ASCO Breast Cancer Guideline Advisory Group and a member of the Resource-Stratified Guideline Advisory Group. She has served as Chair of the Clinical Practice Committee and the Methodology Subcommittee, along with many other volunteer roles, including serving as a grant reviewer and as a member of the Women’s Networking Center Task Force. She is a 2018–2019 participant in ASCO’s Leadership Development Program, and is the recipient of several Merit Awards and the Breast Cancer Advanced Clinical Research Award from Conquer Cancer, the ASCO Foundation.

View current ASCO disclosure here.

Kathleen N. Moore, MD, MS
Board Seat: Designated Surgical Oncologist
x

Dr. Moore is associate director of clinical research, professor of gynecologic oncology, and director of the Oklahoma TSET Phase 1 Program at the Stephenson Cancer Center at the University of Oklahoma. She is a member of ASCO’s Cancer Communications Committee, serves as a journal author and peer reviewer, and is a past member of the Annual Meeting Education Committee and Clinical Practice Committee.

View current ASCO disclosure here.

Ann H. Partridge, MD, MPH, FASCO
Board Seat: Undesignated Member
x

Dr. Partridge is a practicing medical oncologist and clinical researcher. She is vice chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as director of the Adult Survivorship Program and co-founder and director of the Program for Young Women with Breast Cancer. She is a professor at Harvard Medical School and holds the Eric P. Winer Chair in Breast Cancer Research at Dana-Farber. Dr. Partridge has sought to reduce morbidity and mortality from cancer through innovative research, guideline development, dedicated educational efforts, mentoring junior colleagues, and direct patient care. She has led studies focused on cancer disparities, risk perceptions, decision-making, quality of life, adherence with anti-cancer therapy, and cancer survivorship. She is particularly committed to research to reduce disparities in outcomes among young women with breast cancer. Dr. Partridge has served on numerous ASCO committees and initiatives including as Chair of the Clinical Practice Guidelines Committee as well as Chair of the Scientific Program Committee for the 2018 Annual Meeting. She chaired the Center for Disease Control’s Advisory Committee on Breast Cancer in Young Women from 2010-2017 and is leading national clinical research endeavors as co-Chair of the Alliance for Clinical Trials in Oncology Breast Committee and a member of the NCI Breast Cancer Steering Committee. Dr. Partridge is a recipient of a Champions of Change award from the U.S. White House, the AACR Outstanding Investigator Award for Breast Cancer, and ASCO’s Ellen L. Stovall Award for Advancement of Cancer Survivorship Care from Conquer Cancer.

View current ASCO disclosure here.

 

Debra A. Patt, MD, PhD, MBA, FASCO
Board Seat: Designated Community Oncologist
x

Dr. Patt is the executive vice president of Texas Oncology PA and a clinical professor at Dell Medical School at The University of Texas at Austin. She serves as the past-president of the Texas Society of Clinical Oncology (an ASCO State Affiliate) and as editor-in-chief of JCO Clinical Cancer Informatics. Dr. Patt is a member of the ASCO Expert Panels on Systemic Therapy for Advanced HER2+ Breast Cancer and Brain Metastases and Telemedicine Standards, and past member of the Nominating Committee among other volunteer service. She was a 2013-2014 ASCO Leadership Development Program participant and a recipient of both a Young Investigator Award and a Merit Award from Conquer Cancer, the ASCO Foundation. 

View current ASCO disclosure here

Gladys I Rodriguez, MD
Board Seat: Community Oncologist
x

 

Dr. Rodriguez is a medical oncologist and hematologist, Vice President of Clinical Research at South Texas Oncology and Hematology, PA at the START Center for Cancer Care, and Co-Manager of South Texas Accelerated Research Therapeutics (START). She is a member of the Women Who Conquer Cancer Committee. She has served as a member of the ASCO Government Relations Committee, State Affiliate Council, and COVID-19 Road to Recovery Task Force, among other volunteer roles. She was honored as an ASCO Advocacy Champion in 2019 ,2020 and 2022. Dr. Rodriguez is Past President and member of the Texas Society of Clinical Oncology (TxSCO), an ASCO State Affiliate.

View current ASCO disclosure here.

Enrique Soto Pérez de Celis, MD, PhD, MSc, FASCO
Board Seat: International Oncologist
x

Dr. Soto Pérez de Celis is a geriatric oncologist and researcher in the Department of Geriatrics at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City. On the Board, he serves as a liaison to the ASCO Evidence-Base Medicine Commitee, and is a member of the Society’s Finance Committee. He also currently serves on several ASCO committees, including the Journal of Global Oncology Editorial Board, Social Media Working Group, Diversity and Inclusivity Task Force, Technology Research Group, and Publishing Research Group. He has previously served on the AM Education Committee and the Grants Selection Committee. He received a 2019 Conquer Cancer Career Development Award. Previously, Dr. Soto has served on several other ASCO research groups and advisory panels, contributed to the ASCO Connection and ASCO Daily News, and was selected for a Journal of Global Oncology Editorial Fellowship.

Read Dr. Soto’s Q&A on ASCO Connection.

View current ASCO disclosure here.

 

Jennifer S. Temel, MD, FASCO
Board Seat: Undesignated Specialty
x

Dr. Temel is a professor of medicine at Harvard Medical School, clinical director of Thoracic Oncology at the Massachusetts General Hospital, co-director of the Cancer Outcomes Research and Education Program at the Massachusetts General Hospital Cancer Center, and co-leader of the Dana Farber/Harvard Cancer Center Outcomes Research Program. She was the 2018 Walther Cancer Foundation Supportive Oncology Award recipient and the 2005 Conquer Cancer Career Development Award recipient. She is a past member of the Annual Meeting Education Committee and Supportive Care in Oncology Symposium Steering Committee.

View current ASCO disclosure here

Karen Marie Winkfield, MD, PhD, FASCO
Board Seat: Radiation Oncologist
x

Dr. Winkfield is the executive director of the Meharry-Vanderbilt Alliance and a radiation oncologist at Vanderbilt University Medical Center. She is chair of the ASCO Diversity and Inclusivity Task Force. Previously, Dr. Winkfield was a member of the ASCO Government Relations Committee and the ASCO-ACCC Collaboration to Increase Participation of Racial & Ethnic Minority Populations in Cancer, and was an associate editor for Cancer.Net, ASCO’s patient information website. Dr. Winkfield is a past participant in the ASCO Leadership Development Program and was recently appointed by President Joe Biden to serve on the National Cancer Advisory Board.

View current ASCO disclosure here.

Howard A. Burris, MD, FACP, FASCO
Chair, Conquer Cancer Foundation Board (ex-officio)
x

Dr. Burris serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.

Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.

Dr. Burris served as the elected president of ASCO in 2019-2020. He currently serves as the Chair of the Society's Board and also as the Chair of the Board of ASCO’s Conquer Cancer Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.

Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.  

View current ASCO disclosure here.